title: Clinical characteristics of post-treatment reactions to ivermectin/albendazole for Wuchereria bancrofti in a region co-endemic for Mansonella perstans.
abstract: Post-treatment reactions to single-dose ivermectin (200 microg/kg) and albendazole (400 mg) were studied in a filarial endemic region of Mali. The prevalence of Wuchereria bancrofti in this region was 48.3% (69 of 143), and coinfection with Mansonella perstans was common (30 of 40, 75%). Microfilarial levels of M. perstans correlated positively with age (P = 0.006) and with W. bancrofti microfilarial levels (P = 0.006). Forty individuals (28 infected and 12 uninfected) were treated, with mild post-treatment reactions occurring in 35.7% (7 of 28) of the W. bancrofti-infected subjects. Reaction severity correlated with pretreatment W. bancrofti microfilarial levels (P = 0.001). There were no significant differences in the prevalence or severity of post-treatment reactions in those who were co-infected with M. perstans. It is concluded that co-infection with M. perstans does not significantly alter the post-treatment reaction profile to single-dose ivermectin/albendazole in W. bancrofti infection in this community, and that acute post-treatment reactions should not limit patient compliance in community-based programs to eliminate lymphatic filariasis.
authors: Helminth Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-0425, USA.
authors: Paul B
authors: PB
authors: Keiser
authors: Yaya I
authors: YI
authors: Coulibaly
authors: Falaye
authors: F
authors: Keita
authors: Diakaridia
authors: D
authors: Traore
authors: Abdallah
authors: A
authors: Diallo
authors: Dapa A
authors: DA
authors: Diallo
authors: Roshanak T
authors: RT
authors: Semnani
authors: Ogobara K
authors: OK
authors: Doumbo
authors: Sekou F
authors: SF
authors: Traore
authors: Amy D
authors: AD
authors: Klion
authors: Thomas B
authors: TB
authors: Nutman
mesh_terms: D000293:Adolescent; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D000368:Aged; D015766:Albendazole / Q000008:administration & dosage* / Q000009:adverse effects; D000818:Animals; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005368:Filariasis / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D005369:Filaricides / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007559:Ivermectin / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008302:Mali / Q000453:epidemiology; D008366:Mansonella; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D015995:Prevalence; D011795:Surveys and Questionnaires; D014958:Wuchereria bancrofti
chemical_list: D005369:Filaricides; D007559:Ivermectin; D015766:Albendazole